Literature DB >> 17053528

Vascular failure: A new clinical entity for vascular disease.

Teruo Inoue1, Koichi Node.   

Abstract

Atherosclerosis is characterized by the response of the vessel wall to chronic multifactorial injury leading to the formation of atheromatous or fibrous plaques. Endothelial dysfunction represents an initial stage of atherosclerosis. In addition to endothelial dysfunction, smooth muscle dysfunction, metabolic abnormalities of the vessel wall including inflammation, oxidative stress and alterations of neurohormonal balance occur in various stages of atherosclerosis. We now propose a new clinical entity 'vascular failure', defined as the integration of all of these vascular abnormalities. Vascular failure is not an anatomical disease, but rather a comprehensive syndrome of abnormal vascular function. Vascular failure extends from risk factors to established atherosclerotic disease with arterial stenosis, and further to calcification of the vessel wall or serious vascular events that may be caused by plaque rupture and thromboembolic occlusion. We propose aggressive intervention to modify various risk factors, applying to this integrated new entity, vascular failure.

Entities:  

Mesh:

Year:  2006        PMID: 17053528     DOI: 10.1097/01.hjh.0000249684.76296.4f

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  13 in total

1.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.

Authors:  Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

2.  An exaggerated blood pressure response to exercise is associated with nitric oxide bioavailability and inflammatory markers in normotensive females.

Authors:  Ryoma Michishita; Masanori Ohta; Masaharu Ikeda; Ying Jiang; Hiroshi Yamato
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

Review 3.  Cardiovascular injury and repair in chronic obstructive pulmonary disease.

Authors:  William Macnee; John Maclay; David McAllister
Journal:  Proc Am Thorac Soc       Date:  2008-12-01

Review 4.  Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.

Authors:  Allison B Reiss; Benna Jacob; Saba Ahmed; Steven E Carsons; Joshua DeLeon
Journal:  Inflammation       Date:  2021-04-05       Impact factor: 4.092

5.  The impact of OSA and CPAP treatment on cell adhesion molecules' night-morning variation.

Authors:  Olga Nikitidou; Euphemia Daskalopoulou; Aikaterini Papagianni; Emmanuel Vlachogiannis; Nicholas Dombros; Vassilios Liakopoulos
Journal:  Sleep Breath       Date:  2020-10-26       Impact factor: 2.816

6.  Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression.

Authors:  Anselm Mak; Nien Yee Kow; Herbert Schwarz; Lingli Gong; Sen Hee Tay; Lieng Hsi Ling
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

7.  Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE-deficient mice.

Authors:  Hui Sang; Na Yuan; Shutong Yao; Furong Li; Jiafu Wang; Yongqi Fang; Shucun Qin
Journal:  Lipids Health Dis       Date:  2012-12-05       Impact factor: 3.876

Review 8.  Postprandial hyperglycemia as an etiological factor in vascular failure.

Authors:  Koichi Node; Teruo Inoue
Journal:  Cardiovasc Diabetol       Date:  2009-04-29       Impact factor: 9.951

9.  Ethanolic extract of propolis inhibits atherosclerosis in ApoE-knockout mice.

Authors:  Yongqi Fang; Hui Sang; Na Yuan; Hongli Sun; Shutong Yao; Jiafu Wang; Shucun Qin
Journal:  Lipids Health Dis       Date:  2013-08-13       Impact factor: 3.876

10.  Cytochrome P450 1B1 Contributes to the Development of Atherosclerosis and Hypertension in Apolipoprotein E-Deficient Mice.

Authors:  Chi Young Song; Khuzema Ghafoor; Hafiz U Ghafoor; Nayaab S Khan; Shyamala Thirunavukkarasu; Brett L Jennings; Anne M Estes; Sahar Zaidi; Dave Bridges; Patrick Tso; Frank J Gonzalez; Kafait U Malik
Journal:  Hypertension       Date:  2015-11-16       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.